This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus

This study has been completed.
Translumina GmbH
Information provided by:
University of Leipzig Identifier:
First received: August 28, 2006
Last updated: February 1, 2010
Last verified: January 2010

Revascularisation procedures such as percutaneous coronary intervention are associated with overall worse outcomes in patients with diabetes mellitus. Implantation of coronary stents is associated with higher restenosis rates compared to non-diabetic individuals.

There is only limited data available on the efficacy and safety of the novel Yukon Choice drug-eluting stent system specifically in patients with diabetes mellitus. The trial will determine the efficacy and safety of the novel Yukon Choice stent system compared to the well established Taxus Liberté stent system. The primary endpoint will be "in-stent late lumen loss" at 9 months as determined by invasive angiography.

Condition Intervention Phase
Coronary Arteriosclerosis Device: Yukon Choice stent system Device: Taxus Liberté stent system Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Multicenter Comparison of the Drug-Eluting Stent Systems YUKON Choice and TAXUS Liberté in Patients With Diabetes Mellitus

Further study details as provided by University of Leipzig:

Primary Outcome Measures:
  • "In-stent late lumen loss" at follow-up-angiography (9 months) [ Time Frame: 9 months ]

Secondary Outcome Measures:
  • Binary restenosis [ Time Frame: 9 months ]
  • Target vessel revascularisation rate [ Time Frame: 9 months ]
  • Target lesion revascularisation rate [ Time Frame: 9 months ]
  • Late loss (in-segment) [ Time Frame: 9 months ]
  • MLD und diameter of stenosis (%) [ Time Frame: 9 months ]
  • Death [ Time Frame: 9 months ]
  • Success rate index procedure (residual diameter stenosis < 30%) [ Time Frame: 0 months ]
  • Combined MACE (cardiac death, myocardial infarction, emergency bypass, stent thrombosis, target lesion revascularization) [ Time Frame: 9 months ]

Estimated Enrollment: 240
Study Start Date: September 2006
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Device: Yukon Choice stent system
coronary stent implantation
Active Comparator: 2 Device: Taxus Liberté stent system
coronary stent implantation


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age > 18 years
  • diabetes mellitus
  • symptoms (stable or unstable angina pectoris) or objective evidence of myocardial ischemia
  • one or more de novo lesions in 1, 2 or 3 native coronary arteries
  • clinically significant diameter of stenosis (50-99 % according to visual assessment of operator)
  • lesion must be covered by stent length of no more than 24 mm and stent diameter of no more than 3,5 mm
  • vessel diameter of no more than 4 mm in vessel area adjacent to stenosis
  • informed consent

Exclusion Criteria:

  • unprotected left main disease
  • complete occlusion of target vessel
  • in-stent-restenosis
  • stenoses of bypass grafts
  • indication for bypass surgery
  • bifurcation lesions (side branch > 2,0 mm)
  • thrombus in target lesion as visualized by angiography
  • allergy or contraindication to concomitant medication (clopidogrel, aspirin, heparin, contrast media)
  • acute myocardial infarction within preceding 48h
  • participation in another trial
  • pregnancy
  • severe disorder of coagulation or platelet function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00368953

University of Leipzig Heart Center
Leipzig, Germany, 04289
Sponsors and Collaborators
University of Leipzig
Translumina GmbH
Principal Investigator: Holger Thiele, MD Heartcenter Leipzig GmbH
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Holger Thiele, University of Leipzig Identifier: NCT00368953     History of Changes
Other Study ID Numbers: Lipsia-Yukon-DM
Study First Received: August 28, 2006
Last Updated: February 1, 2010

Additional relevant MeSH terms:
Diabetes Mellitus
Coronary Artery Disease
Myocardial Ischemia
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Coronary Disease
Heart Diseases processed this record on June 23, 2017